Ambezim Tablets: A Practical Guide for Orthopedic Patients

Ambezim (Ambezim-G) is an established oral anti-inflammatory and anti-edematous medication designed to accelerate the resolution of localized swelling and tissue fluid accumulation. Each enteric-coated tablet contains a standardized combination of two physiological proteolytic enzymes:

• Chymotrypsin: 5 mg (equivalent to 300 Organic Denominator Units or approx. 14 microkatals).
• Trypsin: 5 mg (equivalent to 2,400 statutory units or approx. 40 microkatals).

Ambezim works via targeted enzymatic debridement and fibrinolytic activity directly at the inflammatory site:

• Enzymatic Fibrinolysis: It degrades fibrinous micro-thrombi and proteinaceous exudates within congested capillary and lymphatic beds.
• Lymphatic Decongestion: By clearing microvascular obstruction, it promotes the rapid drainage of interstitial edema fluid and extravasated blood (hematomas).
• Secondary Pain Relief: Reducing tissue tension and local compartment pressure decreases the mechanical stimulation of sensory nerve endings, relieving throbbing post-injury discomfort.

In musculoskeletal trauma, sports medicine, and reconstructive orthopedic surgery, Ambezim is commonly prescribed to manage:

• Traumatic Injuries: Acute ankle sprains, muscle contusions, deep intramuscular hematomas, and traumatic joint effusions.
• Postoperative Swelling: Tissue edema following major open or minimally invasive procedures, such as arthroscopic ACL reconstruction, rotator cuff repairs, and total knee or hip arthroplasty.
• Fracture Management: Accelerating soft-tissue detumescence prior to open reduction and internal fixation (ORIF) to lower surgical wound complication risks.
• Chronic Tendon & Joint Inflammation: Assisting in the resolution of bursitis, tenosynovitis, and epicondylitis.

Strict adherence to timing guidelines is essential to prevent therapeutic failure:

• Standard Adult Dosage: 1 to 2 tablets taken three times daily, adjusted according to the severity of postoperative or post-injury edema.
• Mandatory Empty Stomach Rule: Tablets must be taken at least 1 hour before meals or 2 hours after meals.
• Rationale: Ingesting Ambezim with food causes the proteolytic enzymes to be consumed in digesting dietary proteins in the digestive tract, preventing their intact systemic absorption into the bloodstream.
• Administration: Swallow tablets whole with a full glass of water.

Ambezim tablets feature a specialized enteric coating engineered to resist gastric hydrochloric acid (HCl):

• Protection Against Acid Degradation: Proteolytic enzymes denature and lose their biochemical potency upon contact with gastric acid. The enteric barrier ensures that the tablet traverses the stomach unchanged.
• Targeted Intestinal Release: The coating dissolves only when it reaches the alkaline environment of the duodenum and upper small intestine, where systemic absorption occurs.
• Do Not Crush or Chew: Crushing, breaking, or chewing the tablet destroys the protective layer, rendering the enzymes therapeutically inactive and risking direct gastric mucosa irritation.

No. Ambezim is an enzymatic anti-edematous agent, not a non-steroidal anti-inflammatory drug (NSAID):

• Different Target: While NSAIDs block prostaglandin synthesis via COX enzyme inhibition to provide direct analgesic and antipyretic effects, Ambezim resolves physical interstitial swelling and microvascular stasis.
• Synergistic Co-prescription: Orthopedic surgeons frequently prescribe Ambezim alongside an NSAID (or paracetamol). This multimodal approach simultaneously tackles biochemical pain generation and mechanical tissue edema without causing additive renal or gastric toxicity.

Ambezim has an established clinical safety profile, but potential adverse effects can occur:

• Gastrointestinal Symptoms: Mild, self-limiting nausea, transient diarrhea, abdominal cramps, or bloating.
• Allergic Reactions: Rarely, sensitized individuals may develop cutaneous hypersensitivity, including skin rashes, hives (urticaria), or itching.
• Vascular Permeability Alterations: Isolated cases of mild transient proteinuria, micro-hematuria, or traces of occult blood in stool have been reported due to enhanced systemic fibrinolysis.

Ambezim should not be administered in the presence of the following medical conditions:

• Known hypersensitivity or idiosyncratic reaction to trypsin, chymotrypsin, or tablet components.
• Active bleeding states or systemic coagulopathies (e.g., severe thrombocytopenia, hemophilia).
• End-stage renal disease or acute hepatic failure.
• Active, unhealed gastrointestinal ulcerations (peptic or duodenal ulcer disease).
• Uncontrolled, acute purulent bacterial infections, unless accompanied by appropriate, culture-directed systemic antibiotic therapy.

Yes, there is an important drug-drug interaction:

Because trypsin and chymotrypsin enhance systemic fibrin breakdown and reduce blood viscosity, their concurrent use with oral anticoagulants (e.g., warfarin, rivaroxaban, apixaban, dabigatran), low-molecular-weight heparins (LMWH), or antiplatelet drugs (e.g., aspirin, clopidogrel) may significantly increase the risk of unexpected surgical or internal bleeding. Always notify your orthopedic surgeon of all concurrent antithrombotic regimens before starting Ambezim.

Special precautions apply during maternal care:

• Pregnancy: Controlled clinical trials assessing the teratogenic or embryotoxic potential of systemic proteolytic enzymes in pregnant women are unavailable. Use during pregnancy—particularly during the critical organogenesis phase of the first trimester—is not recommended unless strictly indicated by the treating physician.
• Lactation: It is unconfirmed whether systemic trypsin and chymotrypsin metabolites are excreted into human breast milk. Breastfeeding patients should avoid the drug or consult their physician for safer, evidence-backed alternatives.